Percutaneous Coronary Intervention

Antiplatelet therapy with ticagrelor after primary PCI for STEMI may confer similar reductions in the composite endpoint of all-cause death, MI and stroke and major bleeding compared with prasugrel, researchers reported.

Lower LDL levels were associated with fewer adverse events among patients with CHD and type 2 diabetes eligible for PCI or CABG, according to results published in the Journal of the American College of Cardiology.

Compared with placebo, icosapent ethyl reduced first and total MACE in patients with prior PCI, according to results from REDUCE-IT PCI presented at the virtual TCT Connect.

Healio and Cardiology Today have curated a list of our top articles of October in cardiology and cardiac/vascular intervention.

Healio and Cardiology Today have curated a list of articles from the virtual TCT Connect.

For patients with ACS, ticagrelor after PCI demonstrated similar rates of net adverse clinical events at 1 year compared with clopidogrel, according to findings published in JAMA.

In the COMPARE CRUSH trial, administration of crushed prasugrel tablets in patients with STEMI on the way to the hospital planned for primary PCI did not improve coronary reperfusion.

A glycoprotein VI inhibitor (Revacept, AdvanceCor) as alternative platelet inhibition strategy during PCI for CAD.

Net adverse clinical events in patients who underwent PCI for ACS according to aspirin-prasugrel (Effient, Daiichi Sankyo/Eli Lilly) strategy.

Recently, there has been renewed interest in the treatment of higher-risk patients undergoing PCI for complex CAD. Novel techniques and equipment have expanded operators’ ability to treat patients with increasingly complicated lesion types.